Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung ...
Candel Therapeutics, Inc. (NASDAQ:CADL) on Wednesday revealed final survival data from a phase 2a trial of CAN-2409 in ...